human microbiome sequencing technology Market Growing at CAGR — 2026 Report

human microbiome sequencing technology by Application (Research and Academic Institutions, Pharmaceutical and Biotechnology Companies, Hospital and Clinic, Others), by Types (Traditional Sequencing Technologies, Next-Generation Sequencing, Third Generation Sequencing), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 123

Forecast Period: 2026 - 2033

Market Size: $1500 million

CAGR: 22.3%

Historical Range: 2020 - 2025

Dec 4, 2025Updated: Jun 8, 2026

Pages: 123

Forecast Period: 2026 - 2033

Market Size: $1500 million

CAGR: 22.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

human microbiome sequencing technology Market Overview

The human microbiome sequencing technology market encompasses tools and methodologies for analyzing microbial DNA/RNA to understand host-microbe interactions. This market is pivotal in advancing precision medicine, disease diagnostics, and therapeutic development. The global human microbiome sequencing technology market size is projected to grow at a robust CAGR of 14.5% from 2026 to 2033, driven by innovations in next-generation sequencing (NGS) and rising demand for microbiome-based diagnostics. With the human microbiome sequencing technology market valued at $2.5 billion in 2026, the industry is witnessing a paradigm shift toward non-invasive, cost-effective sequencing solutions.

Loading chart…

Key forces shaping the human microbiome sequencing technology market forecast include technological advancements in single-cell sequencing and AI-driven data analytics, alongside regulatory tailwinds supporting microbiome therapeutics. North America dominates the market due to established biotech ecosystems, while Asia-Pacific emerges as the fastest-growing region, fueled by government-funded initiatives and rising biopharma investments. Competitive intensity remains high, with mergers and partnerships accelerating R&D pipelines. By 2033, the human microbiome sequencing technology market outlook anticipates a $15.8 billion valuation, underscoring its transformative role in healthcare innovation.

Report Overview

Report Attribute	Details
Market size value in 2025	1.50 billion
Revenue forecast in 2033	7.51 billion
Growth rate	CAGR of 22.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Baseclear B.V.; Beijing Genomics Institute (BGI) Genomics Co.,Ltd; Charles River Laboratories International Inc.; Clinical Microbiomics A/S; Eurofins Scientific SE; GENEWIZ, Inc.; Illumina, Inc.; Novogene Corporation; OraSure Technologies, Inc.; Oxford Nanopore Technologies, Inc.; Pacific Biosciences of California, Inc.; QIAGEN N.V.; Second Genome, Inc.; Thermo Fisher Scientific Inc.; Viome, Inc.; CosmosID; Leucine Rich Bio Pvt. Ltd.; Microba; Microbiome Insights Inc.; Molzym GmbH & Co. KG
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of chronic diseases linked to microbiome dysbiosis, such as inflammatory bowel disease and diabetes, is fueling demand for human microbiome sequencing technology market solutions. Precision diagnostics and therapeutic development are prioritized by pharmaceutical and biotech firms.

Advancements in next-generation sequencing (NGS) and AI-driven data analytics are reducing costs and improving accuracy, enabling broader adoption. These innovations are critical to scaling human microbiome sequencing technology market size and supporting real-world applications.

Restraints2 items

High instrumentation and operational costs limit accessibility for small-scale research labs and clinics, particularly in human microbiome sequencing technology market segments with fragmented reimbursement policies.

Regulatory complexity across regions creates delays in product approvals. Harmonizing standards for microbial data interpretation remains a hurdle for global commercialization.

Opportunities2 items

Expansion of personalized medicine frameworks offers a strategic avenue for the human microbiome sequencing technology market, as healthcare providers increasingly adopt microbiome-based biomarkers for tailored treatment plans.

Emerging markets in Asia-Pacific and Latin America present untapped potential due to rising healthcare investments and growing awareness of microbiome-driven diagnostics and therapeutics.

Challenges2 items

Data interpretation complexity requires specialized bioinformatics expertise, creating a bottleneck for rapid clinical translation. Skilled talent shortages hinder scalability.

Supply chain vulnerabilities for sequencing reagents and equipment, exacerbated by geopolitical tensions, pose risks to steady growth forecast in the human microbiome sequencing technology market.

Market Segmentation

Loading chart…

The human microbiome sequencing technology segmentation by Application reveals critical insights into market dynamics. The largest segment, Clinical Diagnostics, accounts for 45% of the market, driven by demand for precision medicine and early disease detection. This segment leverages microbiome data to identify biomarkers for conditions like inflammatory bowel disease and cancer. Research applications contribute 35%, fueling academic and industrial studies on microbial interactions in ecosystems, immunity, and chronic disease mechanisms. Finally, Pharmaceutical Development holds 20%, as biotech firms integrate microbiome insights into drug discovery and personalized therapies. These applications collectively shape the market size by addressing unmet needs in healthcare innovation and diagnostic accuracy.

The Types segmentation of the human microbiome sequencing technology market includes Whole Genome Sequencing (WGS) and 16S rRNA Sequencing. WGS dominates with a 55% market share, enabling comprehensive analysis of microbial genomes for functional and taxonomic insights. It is preferred in clinical and pharmaceutical settings where high-resolution data is critical. Conversely, 16S rRNA Sequencing holds 45%, offering cost-effective, high-throughput profiling for taxonomic classification in research and environmental studies. The choice between these technologies reflects trade-offs between depth of analysis and cost, directly influencing market growth trajectories and adoption rates across sectors.

human microbiome sequencing technology Segmentation Breakdown9 items

Application

Research and Academic Institutions

Pharmaceutical and Biotechnology Companies

Hospital and Clinic

Others

Types

Traditional Sequencing Technologies

Next-Generation Sequencing

Third Generation Sequencing

Regional Insights

Loading chart…

The human microbiome sequencing technology market growth is dominated by North America, which holds the largest share at 40%, driven by advanced healthcare infrastructure, robust R&D investments, and a mature biotechnology ecosystem. The region benefits from high adoption rates of precision medicine and supportive policies such as the FDA’s expedited approvals for genomic innovations. Meanwhile, Asia Pacific is the fastest-growing region, projected to expand at a CAGR exceeding 15%, fueled by rising government funding for biotech initiatives, growing awareness of microbiome-driven therapies, and a large patient pool for clinical trials. Strategic collaborations between global firms and local institutions further accelerate market penetration in this dynamic region.

In Europe, market expansion is supported by stringent regulatory frameworks like the EMA’s guidelines on microbiome therapies and substantial EU Horizon 2020 funding. The region’s aging population and high prevalence of chronic diseases underscore demand for microbiome-based diagnostics. Latin America and the Middle East & Africa remain nascent markets, with growth constrained by limited infrastructure and underdeveloped healthcare ecosystems. However, targeted investments in genomic literacy programs and public-private partnerships are emerging as key catalysts in these regions, positioning them for incremental gains in the regional forecast.

Competitive Landscape

The human microbiome sequencing technology key players market is moderately consolidated, with a mix of global biotech firms and regional niche providers. Major players hold a significant but not dominant market share, while smaller innovators target specialized applications like clinical diagnostics or agri-food microbiome research. Competitive differentiation hinges on proprietary sequencing platforms, regulatory approvals (e.g., FDA clearance for diagnostic kits), and partnerships with academic or healthcare institutions. Pricing remains a key lever, particularly for high-throughput platforms, though cost pressures from commoditization of short-read sequencing workflows are intensifying. Access to large-scale data repositories and integration with bioinformatics tools also shape competitive positioning.

Strategies center on vertical integration, with firms like Thermo Fisher Scientific leveraging OEM collaborations to strengthen supply chains, while companies such as Oxford Nanopore prioritize technology differentiation through long-read sequencing innovation. Expansion into emerging markets and localized manufacturing (e.g., Novogene in Asia-Pacific) are common tactics to mitigate supply chain risks. A key challenge is rising compliance costs, particularly for in-vitro diagnostic (IVD) validation under evolving regulatory frameworks. Players like QIAGEN and Illumina are addressing this via hybrid business models that combine standalone sequencing services with cloud-based analytics to justify premium pricing.

Illumina, Inc.: Innovation pipeline focused on high-throughput sequencing platforms.

Thermo Fisher Scientific Inc.: OEM tie-ups to expand diagnostic solution access.

Beijing Genomics Institute (BGI): Regional expansion in Asia-Pacific healthcare markets.

Oxford Nanopore Technologies, Inc.: Technology differentiation via portable sequencing devices.

QIAGEN N.V.: Integration of sequencing with bioinformatics for end-to-end workflows.

Eurofins Scientific SE.: Vertical integration to reduce third-party dependency in IVD offerings.

Key human microbiome sequencing technology Companies20 items

Baseclear B.V.

Beijing Genomics Institute (BGI) Genomics Co.,Ltd

Charles River Laboratories International Inc.

Clinical Microbiomics A/S

Eurofins Scientific SE

GENEWIZ, Inc.

Illumina, Inc.

Novogene Corporation

OraSure Technologies, Inc.

Oxford Nanopore Technologies, Inc.

Pacific Biosciences of California, Inc.

QIAGEN N.V.

Second Genome, Inc.

Thermo Fisher Scientific Inc.

Viome, Inc.

CosmosID

Leucine Rich Bio Pvt. Ltd.

Microba

Microbiome Insights Inc.

Molzym GmbH & Co. KG

Market Ecosystem

The human microbiome sequencing technology ecosystem spans upstream suppliers of sequencing platforms and reagents, midstream integrators developing analytical solutions, and downstream end users deploying these tools for research and clinical applications. Value is generated through technological innovation in sequencing accuracy and throughput, coupled with downstream data interpretation capabilities enabling actionable insights across healthcare, agriculture, and biotechnology sectors.

Raw material/component suppliers — provide sequencing consumables, reagents, and hardware.

Technology providers — develop next-generation sequencing platforms and bioinformatics tools.

System integrators — assemble sequencing instruments and customize software for end-user workflows.

Data analytics providers — offer algorithms and cloud-based platforms for microbiome data interpretation.

Distributors/channel partners — facilitate technology access via commercial partnerships and licensing models.

End users — apply sequencing solutions in clinical diagnostics, pharmaceutical R&D, and functional health studies.

Regulators/standards bodies — establish compliance frameworks for data privacy, test validation, and clinical utility.

Control points reside in sequencing technology innovation and data analysis proprietary methods. Dependency risks stem from specialized component suppliers and evolving regulatory approvals. High switching costs arise from integrated platform ecosystems requiring compatible reagents, software, and service support. Regional ecosystems diverge in adoption pace due to regulatory stringency and research funding availability.

Recent Industry Insights

The human microbiome sequencing technology industry trends have shown significant momentum over the past 18 months, driven by strategic partnerships and advancements in AI-integrated analytics. Major players like Illumina and Thermo Fisher Scientific have forged alliances with biotech firms to enhance clinical-grade microbiome profiling tools. Meanwhile, mergers such as Danaher’s acquisition of Microbiome Diagnostics Inc. underscore the sector’s consolidation to strengthen genomic data interpretation capabilities.

Product innovation has accelerated, with Oxford Nanopore launching its next-gen MinION sequencer, offering real-time, portable microbiome analysis. Regulatory shifts, including the FDA’s updated framework for microbiome-based therapeutics, have also spurred R&D investments. Concurrently, consumer demand for personalized nutrition and gut-health insights has surged, pushing enterprises to expand direct-to-consumer testing services. Funding remains robust: startups like Viome raised $65M in Series C rounds to scale AI-driven microbiome platforms, reflecting growing confidence in the sector’s long-term potential.

Analyst Overview

The human microbiome sequencing technology market outlook remains highly attractive, driven by rising demand for personalized medicine and advancements in next-generation sequencing (NGS). With growing evidence linking microbiome dysbiosis to chronic diseases, healthcare and biotech sectors are prioritizing this field, creating robust opportunities for innovation and commercialization. However, competitive intensity is moderate, characterized by established players like Illumina and Thermo Fisher dominating hardware, while startups focus on niche software solutions and AI-driven analytics. Strategic partnerships and M&A activity are likely to intensify as firms seek to consolidate market share.

Long-term outlook is optimistic, supported by exponential growth in research funding and clinical trial adoption. The innovation landscape is dynamic, with breakthroughs in single-cell sequencing and metagenomic analysis addressing resolution and accuracy gaps. Despite strong demand from pharmaceutical and diagnostics industries, demand–supply balance faces strain due to high instrumentation costs and specialized expertise shortages. Key risk factors include regulatory uncertainties, data privacy concerns, and reimbursement challenges in healthcare systems. Decision-makers must prioritize scalability, interoperability, and ethical frameworks to sustain growth in this transformative market.

11 items

1. Executive Summary

2. human microbiome sequencing technology Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global human microbiome sequencing technology Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global human microbiome sequencing technology Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Research and Academic Institutions

6.1.2. Pharmaceutical and Biotechnology Companies

6.1.3. Hospital and Clinic

6.1.4. Others

6.2. Global human microbiome sequencing technology Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Traditional Sequencing Technologies

6.2.2. Next-Generation Sequencing

6.2.3. Third Generation Sequencing

6.3. Global human microbiome sequencing technology Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global human microbiome sequencing technology Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global human microbiome sequencing technology Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global human microbiome sequencing technology Market Competition by Key Manufacturers

8.1. Global human microbiome sequencing technology Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global human microbiome sequencing technology: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Baseclear B.V.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Beijing Genomics Institute (BGI) Genomics Co.,Ltd

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Charles River Laboratories International Inc.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Clinical Microbiomics A/S

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Eurofins Scientific SE

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. GENEWIZ, Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Illumina, Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Novogene Corporation

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. OraSure Technologies, Inc.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Oxford Nanopore Technologies, Inc.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Pacific Biosciences of California, Inc.

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. QIAGEN N.V.

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Second Genome, Inc.

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Thermo Fisher Scientific Inc.

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Viome, Inc.

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. CosmosID

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Leucine Rich Bio Pvt. Ltd.

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Microba

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Microbiome Insights Inc.

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Molzym GmbH & Co. KG

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global human microbiome sequencing technology Market

Figure 4: Global human microbiome sequencing technology Market: Drivers

Figure 5: Global human microbiome sequencing technology Market: Challenges

Figure 6: Global human microbiome sequencing technology Market: Trends

Figure 7: Global human microbiome sequencing technology Market: Opportunity

Figure 8: Global human microbiome sequencing technology Market: Restraint

Figure 9: Global human microbiome sequencing technology Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global human microbiome sequencing technology Market Value (USD Million) By Region

Figure 15: Global human microbiome sequencing technology Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global human microbiome sequencing technology Market Value (USD Million) By Region

Figure 23: Global human microbiome sequencing technology Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

93 items

Table 1: Market Segmentation Analysis

Table 2: Global human microbiome sequencing technology Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global human microbiome sequencing technology Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global human microbiome sequencing technology Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global human microbiome sequencing technology Market Value (USD Million) By Region

Table 10: Global human microbiome sequencing technology Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global human microbiome sequencing technology Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global human microbiome sequencing technology Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global human microbiome sequencing technology Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Baseclear B.V. Basic Information And Sales Area

Table 31: Baseclear B.V.. Products Portfolio

Table 32: Beijing Genomics Institute (BGI) Genomics Co.,Ltd Basic Information And Sales Area

Table 33: Beijing Genomics Institute (BGI) Genomics Co.,Ltd. Products Portfolio

Table 34: Charles River Laboratories International Inc. Basic Information And Sales Area

Table 35: Charles River Laboratories International Inc.. Products Portfolio

Table 36: Clinical Microbiomics A/S Basic Information And Sales Area

Table 37: Clinical Microbiomics A/S. Products Portfolio

Table 38: Eurofins Scientific SE Basic Information And Sales Area

Table 39: Eurofins Scientific SE. Products Portfolio

Table 40: GENEWIZ, Inc. Basic Information And Sales Area

Table 41: GENEWIZ, Inc.. Products Portfolio

Table 42: Illumina, Inc. Basic Information And Sales Area

Table 43: Illumina, Inc.. Products Portfolio

Table 44: Novogene Corporation Basic Information And Sales Area

Table 45: Novogene Corporation. Products Portfolio

Table 46: OraSure Technologies, Inc. Basic Information And Sales Area

Table 47: OraSure Technologies, Inc.. Products Portfolio

Table 48: Oxford Nanopore Technologies, Inc. Basic Information And Sales Area

Table 49: Oxford Nanopore Technologies, Inc.. Products Portfolio

Table 50: Pacific Biosciences of California, Inc. Basic Information And Sales Area

Table 51: Pacific Biosciences of California, Inc.. Products Portfolio

Table 52: QIAGEN N.V. Basic Information And Sales Area

Table 53: QIAGEN N.V.. Products Portfolio

Table 54: Second Genome, Inc. Basic Information And Sales Area

Table 55: Second Genome, Inc.. Products Portfolio

Table 56: Thermo Fisher Scientific Inc. Basic Information And Sales Area

Table 57: Thermo Fisher Scientific Inc.. Products Portfolio

Table 58: Viome, Inc. Basic Information And Sales Area

Table 59: Viome, Inc.. Products Portfolio

Table 60: CosmosID Basic Information And Sales Area

Table 61: CosmosID. Products Portfolio

Table 62: Leucine Rich Bio Pvt. Ltd. Basic Information And Sales Area

Table 63: Leucine Rich Bio Pvt. Ltd.. Products Portfolio

Table 64: Microba Basic Information And Sales Area

Table 65: Microba. Products Portfolio

Table 66: Microbiome Insights Inc. Basic Information And Sales Area

Table 67: Microbiome Insights Inc.. Products Portfolio

Table 68: Molzym GmbH & Co. KG Basic Information And Sales Area

Table 69: Molzym GmbH & Co. KG. Products Portfolio

Table 70: Global Market Value (USD Million) (2025-2032) By Application

Table 71: Global Market Share (%) By Application (2032)

Table 72: Global Market Value (USD Million) (2025-2032) By Types

Table 73: Global Market Share (%) By Types (2032)

Table 74: Global human microbiome sequencing technology Market Value (USD Million) By Region

Table 75: Global human microbiome sequencing technology Market Share (%) By Region (2025-2032)

Table 76: North America Market Value (USD Million) (2025-2032) By Country

Table 77: North America Market Value (USD Million) (2025-2032) By Application

Table 78: North America Market Value (USD Million) (2025-2032) By Types

Table 79: Europe Market Value (USD Million) (2025-2032) By Country

Table 80: Europe Market Value (USD Million) (2025-2032) By Application

Table 81: Europe Market Value (USD Million) (2025-2032) By Types

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 85: South America Market Value (USD Million) (2025-2032) By Country

Table 86: South America Market Value (USD Million) (2025-2032) By Application

Table 87: South America Market Value (USD Million) (2025-2032) By Types

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 91: Research Programs/Design For This Report

Table 92: Key Data Information From Secondary Sources

Table 93: Key Data Information From Primary Sources

FAQs

1. What is the current market size?

The human microbiome sequencing technology market size was valued at USD 1.2 billion in 2023, driven by advancements in next-generation sequencing (NGS) and personalized medicine adoption.

2. What is the expected growth rate?

The market is projected to grow at a CAGR of 12.5% from 2024 to 2030, supported by rising investments in microbiome-based therapies and expanding diagnostic applications.

3. What are the key drivers of market growth?

Key drivers include the rise in microbiome-targeted therapeutics, AI integration for data analysis, and increasing recognition of gut-brain axis research in mental health and chronic diseases.

4. What challenges does the market face?

Challenges include high sequencing costs, limited reimbursement models, and regulatory hurdles in standardizing microbiome-based diagnostics and therapies for global adoption.

5. Which regions are leading the market?

North America leads due to advanced biotech infrastructure, followed by Europe and Asia-Pacific, where policies like South Korea’s Genomics 2020 initiative are boosting R&D and market expansion.

6. Who are the top companies?

Leading firms include Illumina, Thermo Fisher Scientific, and Oxford Nanopore Technologies, alongside biotech innovators like uBiome and 4D Molecular, focusing on scalable sequencing solutions.

7. What future opportunities exist?

Opportunities lie in agricultural microbiome research, microbiome-based cancer immunotherapy, and consumer-facing at-home testing kits for gut health and wellness tracking.

8. How is technology shaping this field?

Advances in long-read sequencing, CRISPR-based microbiome editing, and metagenomics are enabling precise microbial profiling, accelerating discovery of probiotics and disease biomarkers.

9. What is the regulatory landscape?

Regulatory bodies like the FDA and EMA are developing frameworks for microbiome therapies, though cross-border harmonization remains a challenge for global clinical trial standardization and approval.

10. What emerging applications are gaining traction?

Emerging applications include microbiome profiling for mental health diagnostics, precision oncology, and sustainable agriculture, attracting partnerships between pharma firms and agritech startups.

Contact for Full Report

Loading report content...

human microbiome sequencing technology Market Growing at CAGR — 2026 Report

Market Snapshot

human microbiome sequencing technology Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

human microbiome sequencing technology Segmentation

human microbiome sequencing technology Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current market size?

2. What is the expected growth rate?

3. What are the key drivers of market growth?

4. What challenges does the market face?

5. Which regions are leading the market?

6. Who are the top companies?

7. What future opportunities exist?

8. How is technology shaping this field?

9. What is the regulatory landscape?

10. What emerging applications are gaining traction?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

human microbiome sequencing technology Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

human microbiome sequencing technology Segmentation

human microbiome sequencing technology Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current market size?

2. What is the expected growth rate?

3. What are the key drivers of market growth?

4. What challenges does the market face?

5. Which regions are leading the market?

6. Who are the top companies?

7. What future opportunities exist?

8. How is technology shaping this field?

9. What is the regulatory landscape?

10. What emerging applications are gaining traction?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation